Revolutionizing Hyperbaric Oxygen Therapy: BARIKS Unveils Game-Changing Portable Chambers

BARIKS, an Israeli pioneer in Hyperbaric Oxygen Therapy (HBOT), introduces a game-changing innovation: a patented, portable, foldable hyperbaric chamber operating at a working pressure of 3 atmospheres. This chamber promises to transform HBOT treatment and its accessibility.

In an exclusive interview with Yoav Blat, BARIKS’ Representative in North America, we explore the technology behind this chamber and its potential to revolutionize and redefine the HBOT Landscape.

After an intensive four-year development, BARIKS is set to launch its state-of-the-art chambers in early 2024. Traditionally, Hyperbaric Oxygen Therapy (HBOT), known for its remarkable healing potential and diverse medical contexts, has been confined to specialized medical facilities.

Differing from traditional methods involving large multi-place chambers or less innovative monoplace chambers, BARIKS’ solution transcends the 2 ATA pressure barrier, enabling transformative treatments. Its applications span medical care, cognitive enhancement, sports medicine, anti-aging, and aesthetics while enhancing overall quality of life.

BARIKS’ achievement is poised to reshape HBOT, unlocking new dimensions of healing and wellness.

Our chamber design embodies innovation, folding into a suitcase within minutes, fitting into a car trunk, and weighing a mere 25 kilograms. This eliminates the necessity for hospital visits, making treatments convenient wherever you are.

Integrated software enhances our chamber, offering personalized treatments and precise data analysis to cater to individual preferences and meet stringent medical monitoring standards.

BARIKS’ commitment to pioneering technology propels the future of hyperbaric therapy, ensuring accessibility and efficacy for all by democratizing access to this transformative therapy.

Patents and Grants

Our technologies are fortified by patents, including co-invention of chamber body material with an Israeli specialist factory exclusively owned by Bariks.

Our software platform features robust security mechanisms and a patented distinct approach to HBOT.

Bariks secured a substantial grant from the Israel Innovation Authority.  $1 million annually for three years. This underscores our technological potential and exceptional team. The Authority’s stringent due diligence process sets a high standard for investors and collaborators.

The Visionary Team Driving BARIKS’ Innovation

Admiral Yedidya Ya‘ari – Co-Chairman, Former CEO of Rafael Advanced Defense Systems, and commander of the Israeli Navy

Boaz Misholi – Co-Chairman Tech entrepreneur with a legacy of success,

Dr. Yehuda Melamed – Medical Director, Pioneering hyperbaric medicine expert

Amir Shukrun – CEO, Vast experience in private equity and management.

A Vision for the Future

The BARIKS Team, armed with extensive expertise, spearheads the HBOT revolution.

The company’s financial projections indicate a promising future, with robust growth anticipated. Sales are projected to reach hundreds of millions over the next few years, propelling BARIKS to a substantial valuation. This will be supported by a strong balance sheet and successful operations, crucial in today’s valuation landscape.

BARIKS is ready to usher in a transformative era in Hyperbaric Oxygen Therapy, positioning itself as a pioneering innovator and introducing accessible and effective treatment options for all.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”